Takeda Pharmaceutical Co Ltd - Q1 FY2021 Summary
Business Context and Reporting Period
This Form 6-K reports the Quarterly Securities Report for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2021 (First Quarter of the 145th Business Term). The report was filed on August 6, 2021. Takeda is a global biopharmaceutical company focused on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. During the period, the company completed the sale of a diabetes product portfolio in Japan and continued divestitures of non-core assets.
Key Financial Metrics
| Metric (JPY Millions) | Q1 FY2020 | Q1 FY2021 | Change |
|---|---|---|---|
| Revenue | 801,850 | 949,603 | +18.4% |
| Operating Profit | 167,285 | 248,552 | +48.6% |
| Profit Before Tax | 130,291 | 222,978 | +71.1% |
| Net Profit (Period) | 82,519 | 137,726 | +66.9% |
| Net Profit (Attributable to Owners) | 82,511 | 137,684 | +66.8% |
| Basic EPS (JPY) | 52.93 | 87.96 | +66.2% |
| Operating Cash Flow | 145,861 | 166,858 | +14.4% |
| Cash & Equivalents (End) | 589,787 | 654,920 | +11.0% |
| Total Debt (Bonds & Loans) | 4,635,371 | 4,405,861 | -4.9% |
Note: Debt figures represent the carrying amount of Bonds and Loans as of the period end.
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 18.4% year-over-year. This was significantly driven by a one-time 133.0 billion JPY gain from the sale of a diabetes product portfolio in Japan to Teijin Pharma Limited. Excluding this transaction and foreign exchange impacts, underlying revenue growth was 3.8%.
- Profitability: Operating profit surged 48.6% to 248.6 billion JPY. This increase was aided by a significant decrease in "Other Operating Expenses" (down 44.9%) due to the absence of a 18.6 billion JPY loss related to contingent consideration from the prior year's XIIDRA divestment.
- Therapeutic Area Performance:
- Gastroenterology: Revenue up 12.6%, driven by ENTYVIO (+23.9%) and TAKECAB (+20.1%).
- Oncology: Revenue up 12.4%, led by VELCADE (+24.6%) and ADCETRIS (+14.2%).
- Neuroscience: Revenue up 6.1%, with VYVANSE/ELVANSE up 20.0%.
- Rare Diseases: Flat growth (+0.3%) due to declines in Rare Hematology offset by growth in Rare Metabolic and Hereditary Angioedema.
- Debt Reduction: Total bonds and loans decreased by 229.5 billion JPY due to the redemption of senior notes and prepayment of a Japan Bank for International Cooperation loan.
Guidance, Outlook, and Risks
- Underlying Metrics: Management highlights "Underlying Core Operating Profit" of 248.9 billion JPY (margin 30.5%) and "Underlying Core EPS Growth" of +3.9%. Underlying Core Operating Profit growth was -2.1% due to increased R&D investment.
- COVID-19 Impact: The pandemic did not have a material negative effect on financial results for the quarter. The company resumed most clinical trial activities and is distributing the Moderna COVID-19 vaccine in Japan under a partnership agreement.
- R&D Pipeline: Significant progress includes FDA priority review for mobocertinib (lung cancer), approval of NINLARO maintenance therapy in Japan, and Breakthrough Therapy Designation for TAK-994 (narcolepsy). The Phase 3 trial for CoVIg-19 (hyperimmune immunoglobulin) did not meet endpoints.
- Contingencies & Risks:
- Irish Tax Assessment: Takeda recorded a tax provision of 472 million EUR (approx. 62.7 billion JPY) following an adverse ruling by the Irish Tax Appeals Commission regarding a break fee from a 2014 AbbVie offer. Takeda intends to appeal.
- Litigation: Settled patent litigation regarding ADYNOVATE with Bayer; the settlement had no material impact as provisions were previously established.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue growth by excluding the 133.0 billion JPY one-time gain from the Japan diabetes portfolio sale.
- Underlying Growth: Review the reconciliation of reported to underlying revenue and profit to assess core business performance (Underlying Revenue Growth +3.8%).
- Tax Contingency: Monitor the status of the appeal regarding the Irish Revenue Commissioners' tax assessment on the AbbVie break fee.
- Debt Management: Confirm the impact of recent debt prepayments (2.0 billion USD loan and 200 million USD notes) on future liquidity and interest expenses.
- Product Lifecycle: Assess the impact of generic erosion on key products like AMITIZA, FIRAZYR, and LEUPLIN/ENANTONE.